Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. The trade was a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $5.81 on Friday. The firm has a market capitalization of $894.39 million, a PE ratio of -12.91 and a beta of 2.32. The company’s 50-day moving average is $3.88 and its 200-day moving average is $3.40. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.69 and a fifty-two week high of $5.92.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on XERS shares. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Craig Hallum lifted their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Leerink Partners lifted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average price target of $5.92.

Institutional Trading of Xeris Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of XERS. Walleye Capital LLC bought a new stake in shares of Xeris Biopharma during the 3rd quarter worth about $3,197,000. JPMorgan Chase & Co. boosted its holdings in shares of Xeris Biopharma by 166.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company’s stock worth $3,537,000 after buying an additional 651,481 shares during the period. Driehaus Capital Management LLC bought a new stake in shares of Xeris Biopharma during the 4th quarter worth about $2,014,000. Millennium Management LLC boosted its holdings in shares of Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock worth $6,606,000 after buying an additional 502,853 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock worth $7,115,000 after buying an additional 500,120 shares during the period. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.